Newsfiscal.ai
Acrivon Therapeutics to Present Phase 1/2 Data for ACR-2316 at EORTC-NCI-AACR Symposium
· Published
Article summary
Acrivon Therapeutics announced that dose escalation data from its Phase 1/2 study of ACR-2316, a WEE1/PKMYT1 inhibitor, will be presented at the 38th EORTC-NCI-AACR Symposium.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…